Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2004;110:1387-1391
Published online before print September 7, 2004, doi: 10.1161/01.CIR.0000141295.60857.30
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
110/11/1387    most recent
01.CIR.0000141295.60857.30v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Suzuki, S.
Right arrow Articles by Ogawa, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Suzuki, S.
Right arrow Articles by Ogawa, H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Heart Attack
Related Collections
Right arrow Hypertrophy
Right arrow Clinical Studies
Right arrow Echocardiography

(Circulation. 2004;110:1387-1391.)
© 2004 American Heart Association, Inc.


Original Articles

Plasma Level of B-Type Natriuretic Peptide as a Prognostic Marker After Acute Myocardial Infarction

A Long-Term Follow-Up Analysis

Satoru Suzuki, MD; Michihiro Yoshimura, MD; Masafumi Nakayama, MD; Yuji Mizuno, MD; Eisaku Harada, MD; Teruhiko Ito, MD; Shota Nakamura, MD; Koji Abe, MD; Megumi Yamamuro, MD; Tomohiro Sakamoto, MD; Yoshihiko Saito, MD; Kazuwa Nakao, MD; Hirofumi Yasue, MD; Hisao Ogawa, MD

From the Department of Cardiovascular Medicine (S.S., M. Yoshimura, M.N., S.N., K.A., M. Yamamuro, T.S., H.O.), Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan; Division of Cardiology (Y.M., E.H., T.I., H.Y.), Kumamoto Aging Research Institute, Kumamoto, Japan; First Department of Internal Medicine (Y.S.), Nara Medical University, Nara, Japan; and Department of Medicine and Clinical Science (K.N.), Kyoto University Graduate School of Medicine, Kyoto, Japan.

Reprint requests to Michihiro Yoshimura, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan. E-mail bnp{at}kumamoto-u.ac.jp

Received January 16, 2004; de novo received March 30, 2004; revision received May 4, 2004; accepted May 6, 2004.

Background— Circulating levels of B-type natriuretic peptide (BNP), a cardiac hormone, reflect the severity of cardiac dysfunction. Because the plasma BNP level changes dramatically during the period after the onset of acute myocardial infarction (AMI), identification of a suitable sampling time is problematic. There have been several reports indicating that the plasma BNP level obtained in the acute phase of AMI can be used as a prognostic marker. We examined whether the plasma BNP level measured 3 to 4 weeks after the onset of AMI represents a reliable prognostic marker for patients with AMI.

Methods and Results— We analyzed 145 consecutive patients with AMI. Plasma BNP levels were measured during the 3 to 4 weeks after onset of AMI. Of those patients, 23 experienced fatal cardiac events during this study. The mean follow-up period was 58.6 months. Log BNP, left ventricular end-diastolic pressure, and pulmonary vascular resistance were all significantly higher in the cardiac death group, and there were more men and more patients with a history of heart failure in the cardiac death group. A Cox proportional hazards model analysis showed that log BNP was an independent predictor of cardiac death. The survival rate was significantly higher in patients with log BNP <2.26 (180 pg/mL) than in those with log BNP ≥2.26.

Conclusions— The plasma BNP level obtained 3 to 4 weeks after the onset of AMI can be used as an independent predictor of cardiac death in patients with AMI.


Key Words: natriuretic peptides • myocardial infarction • prognosis




This article has been cited by other articles:


Home page
Hum Mol GenetHome page
A. Marchini, B. Hacker, T. Marttila, V. Hesse, J. Emons, B. Weiss, M. Karperien, and G. Rappold
BNP is a transcriptional target of the short stature homeobox gene SHOX
Hum. Mol. Genet., December 15, 2007; 16(24): 3081 - 3087.
[Abstract] [Full Text] [PDF]


Home page
Eur J EchocardiogrHome page
I. Karabinos, E. Karvouni, N. Chiotinis, A. Papadopoulos, P. Simeonidis, O. Tsolas, and D. Katritsis
Acute changes in N-terminal pro-brain natriuretic peptide induced by dobutamine stress echocardiography
Eur J Echocardiogr, August 1, 2007; 8(4): 265 - 274.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. Kasama, T. Toyama, T. Hatori, H. Sumino, H. Kumakura, Y. Takayama, S. Ichikawa, T. Suzuki, and M. Kurabayashi
Effects of Intravenous Atrial Natriuretic Peptide on Cardiac Sympathetic Nerve Activity and Left Ventricular Remodeling in Patients With First Anterior Acute Myocardial Infarction
J. Am. Coll. Cardiol., February 13, 2007; 49(6): 667 - 674.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Sato, K. Aonuma, K. Imanaka-Yoshida, T. Yoshida, M. Isobe, D. Kawase, N. Kinoshita, Y. Yazaki, and M. Hiroe
Serum Tenascin-C Might Be a Novel Predictor of Left Ventricular Remodeling and Prognosis After Acute Myocardial Infarction
J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2319 - 2325.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]


Home page
Eur Heart JHome page
C. J. Terkelsen, B. L. Norgaard, J. F. Lassen, S. H. Poulsen, J. C. Gerdes, E. Sloth, L. B.-H. Gotzsche, F. K. Romer, L. Thuesen, T. T. Nielsen, et al.
Potential significance of spontaneous and interventional ST-changes in patients transferred for primary percutaneous coronary intervention: observations from the ST-MONitoring in Acute Myocardial Infarction study (The MONAMI study)
Eur. Heart J., February 1, 2006; 27(3): 267 - 275.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
W. Wojakowski, M. Tendera, A. Zebzda, A. Michalowska, M. Majka, M. Kucia, K. Maslankiewicz, R. Wyderka, M. Krol, A. Ochala, et al.
Mobilization of CD34+, CD117+, CXCR4+, c-met+ stem cells is correlated with left ventricular ejection fraction and plasma NT-proBNP levels in patients with acute myocardial infarction
Eur. Heart J., February 1, 2006; 27(3): 283 - 289.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Luchner, C. Hengstenberg, H. Lowel, G. A.J. Riegger, H. Schunkert, and S. Holmer
Effect of Compensated Renal Dysfunction on Approved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and N-Terminal Pro-BNP
Hypertension, July 1, 2005; 46(1): 118 - 123.
[Abstract] [Full Text] [PDF]